Sarcoma Clinical Trial
Official title:
A Phase II Study of Aerosolized GM-CSF (NSC# 613795, IND# 11042) in Patients With First Pulmonary Recurrence of Osteosarcoma
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the
growth of tumor cells and shrink the tumor so that it can be removed during surgery.
Sargramostim may then kill any tumor cells remaining after surgery. This may be an effective
treatment for osteosarcoma that has spread to the lung.
PURPOSE: This phase II trial is studying how well inhaled sargramostim works in treating
patients who are undergoing surgery for the first recurrence of osteosarcoma that has spread
to the lung.
OBJECTIVES:
Primary
- Assess the histological findings from patients with first pulmonary recurrence of
osteosarcoma who undergo resection of pulmonary metastases after treatment with 2
courses of aerosolized sargramostim (GM-CSF).
- Determine the event-free survival of patients treated with this drug.
- Determine whether the maximum tolerated dose in the trial of inhaled GM-CSF in adult
patients with melanoma is tolerable in pediatric patients.
Secondary
- Determine the effect of specific thoracic surgical management on outcome in patients
treated with this drug.
OUTLINE: This is a multicenter, dose escalation study. Patients are assigned to 1 of 2
groups according to the extent of pulmonary recurrence (unilateral or bilateral).
- Group I (unilateral recurrence):
- Initial inhalation therapy: Patients receive inhaled sargramostim (GM-CSF) twice
daily on days 1-7. Treatment repeats every other week every 14 days for a total of
2 courses.
- Thoracotomy: Patients undergo thoracotomy on day 22.
- Post-thoracotomy inhalation therapy: Beginning on day 29, or as soon as possible
thereafter, patients resume inhalation therapy as above for up to 12 additional
courses.
- Group II (bilateral recurrence): Patients may be enrolled on study either before or
after the first thoracotomy.
- First thoracotomy: Patients undergo unilateral thoracotomy.
- Initial inhalation therapy: Patients receive inhaled GM-CSF, as soon as possible
after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats
every other week every 14 days for a total of 2 courses.
- Contralateral thoracotomy: Patients undergo contralateral thoracotomy on day 22.
- Post-thoracotomy inhalation therapy: Beginning on day 29, or as soon as possible,
patients resume inhalation therapy as above for up to 12 additional courses.
Treatment in both groups continues in the absence of disease progression or unacceptable
toxicity.
Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months
for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 1.6-2 years.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
| Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
| Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
| Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
| Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
| Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
| Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
| Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
| Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |